What it's for (Indications)
- Nitrofurantoin (e.
- g.
- , Furantin) is an antibacterial agent indicated for the treatment and prophylaxis of uncomplicated urinary tract infections (UTIs) caused by susceptible strains of specific microorganisms.
- Its primary indications include acute cystitis and prophylaxis of recurrent UTIs.
- The susceptible pathogens commonly include Escherichia coli, Enterococci (e.
- g.
- , Enterococcus faecalis), Staphylococcus saprophyticus, and certain Klebsiella and Enterobacter species.
- It is important to note that nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses, as it does not achieve therapeutic concentrations in renal parenchyma or systemic circulation.
- Proper susceptibility testing should guide therapy, though empirical use for uncomplicated cystitis is often warranted given its typical efficacy against common uropathogens.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage regimens for nitrofurantoin vary based on the specific formulation (macrocrystals or monohydrate/macrocrystals), the patient's age, and the clinical indication. For adults with acute uncomplicated urinary tract infections, the typical dosage for nitrofurantoin monohydrate/macrocrystals (e.g., Macrobid) is 100 mg orally every 12 hours for 5 to 7 days. For nitrofurantoin macrocrystals (e.g., Macrodantin), the dosage is 50 to 100 mg orally four times a day for 7 days. For the prophylaxis of recurrent UTIs in adults, a dose of 50 to 100 mg orally once daily at bedtime is often prescribed. Pediatric dosing for acute uncomplicated UTIs generally ranges from 5 to 7 mg/kg/day in four divided doses for macrocrystals, or 100 mg every 12 hours for monohydrate/macrocrystals, for 5 to 7 days. Prophylactic pediatric dosing is typically 1 to 2 mg/kg/day orally once daily. It is crucial to administer nitrofurantoin with food to enhance absorption and minimize gastrointestinal upset. Dosage adjustments are critical in patients with impaired renal function, and it is contraindicated in severe renal impairment. |
Safety & Warnings
Common Side Effects
- Common adverse effects associated with nitrofurantoin therapy primarily involve the gastrointestinal system, including nausea, vomiting, diarrhea, abdominal pain, and anorexia.
- These effects can often be mitigated by taking the medication with food or milk.
- Urine discoloration (yellow to brown) is a common and harmless side effect.
- More serious, albeit less common, adverse effects include pulmonary reactions (acute, subacute, or chronic), which can manifest as pneumonitis, pulmonary fibrosis, or asthma-like symptoms; these can be severe and require immediate discontinuation.
- Hepatotoxicity, ranging from transient elevations in liver enzymes to cholestatic jaundice, chronic active hepatitis, and hepatic necrosis (some fatal), has been reported.
- Peripheral neuropathy, characterized by paresthesias and weakness, can be debilitating and irreversible, especially in patients with renal impairment, diabetes, or other risk factors.
- Hematologic reactions such as hemolytic anemia (particularly in G6PD deficient individuals), megaloblastic anemia, leukopenia, and thrombocytopenia may occur.
- Hypersensitivity reactions, including skin rashes, urticaria, angioedema, and in rare instances, severe cutaneous adverse reactions like Stevens-Johnson syndrome or DRESS syndrome, have also been observed.
Serious Warnings
- Black Box Warning: While nitrofurantoin does not carry an FDA Black Box Warning, healthcare professionals and patients must be acutely aware of several serious adverse reactions that warrant significant caution and careful patient selection. These include severe and potentially irreversible pulmonary reactions, such as acute, subacute, and chronic pneumonitis, and pulmonary fibrosis, which can be life-threatening. Significant hepatotoxicity, encompassing cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, some of which have resulted in fatalities, has been reported. Furthermore, debilitating peripheral neuropathy, which can be irreversible, is a notable risk, particularly amplified in patients with renal impairment (creatinine clearance <60 mL/min), diabetes mellitus, anemia, electrolyte imbalance, vitamin B deficiency, or other debilitating conditions. Hemolytic anemia is also a serious concern, especially in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. These serious adverse effects necessitate rigorous patient assessment, ongoing monitoring for signs and symptoms of toxicity, and prompt discontinuation of the drug if these reactions occur. The risks of chronic pulmonary and hepatic toxicities are increased with prolonged therapy.
- Nitrofurantoin use necessitates careful consideration of several serious potential adverse effects.
- Pulmonary toxicity, encompassing acute, subacute, and chronic reactions (e.
- g.
- , interstitial pneumonitis, pulmonary fibrosis), can be severe, progressive, and, in some cases, fatal.
- Chronic reactions typically develop after prolonged therapy and may be insidious.
- Hepatotoxicity, including chronic active hepatitis and cholestatic jaundice, has been reported, with some fatalities.
- Liver function should be monitored, especially during prolonged treatment.
- Peripheral neuropathy, which can be severe, irreversible, and potentially fatal, is a significant concern, particularly in patients with pre-existing conditions like renal impairment (creatinine clearance <60 mL/min), anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, or other debilitating diseases.
- Hemolytic anemia can occur, especially in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency; appropriate screening is recommended for at-risk populations.
- Furthermore, like many antibacterials, nitrofurantoin can alter the normal flora of the colon, leading to Clostridium difficile-associated diarrhea (CDAD), which can range in severity from mild diarrhea to fatal colitis.
- Prolonged use of nitrofurantoin may also result in the overgrowth of non-susceptible organisms.
- Caution is advised in elderly patients due to their increased susceptibility to pulmonary, hepatic, and neurological adverse effects.
How it Works (Mechanism of Action)
Nitrofurantoin functions as an antibacterial agent through a unique mechanism that involves its reduction by bacterial flavoproteins. Once inside the bacterial cell, nitrofurantoin is rapidly reduced to highly reactive intermediates that indiscriminately inactivate or damage multiple bacterial components. These critical cellular targets include ribosomal proteins, DNA, RNA, and various other essential metabolic enzymes. This broad-spectrum attack on multiple macromolecules within the bacterium effectively inhibits protein synthesis, aerobic energy metabolism, DNA and RNA synthesis, and cell wall synthesis, ultimately leading to bacterial cell death or growth inhibition. The multi-targeted action of nitrofurantoin significantly reduces the likelihood of developing bacterial resistance compared to antibiotics with more specific targets. Nitrofurantoin is primarily bacteriostatic at lower concentrations and bactericidal at higher concentrations. Its efficacy is particularly pronounced in the urinary tract because it concentrates in the urine, reaching therapeutic levels within the bladder, while systemic levels remain relatively low, minimizing widespread antibacterial effects outside the urinary system.